Non-Erosive Reflux Disease (NERD) / Reflux Hypersensitivity

Non-erosive reflux disease (NERD) is the phenotype of gastroesophageal reflux disease in which a patient has troublesome reflux symptoms — classically heartburn and regurgitation — but no mucosal breaks (erosions) are seen on upper endoscopy (Fass et al., Nature Reviews Disease Primers, 2021). It is by far the most common presentation of GERD: among all patients with reflux disease, roughly 60–70% have the non-erosive form, compared with about 30% who have erosive esophagitis and a smaller group who have Barrett's esophagus (Fass, New England Journal of Medicine, 2022). Because the esophagus looks normal, NERD is frequently misunderstood as "mild" reflux — but a normal endoscopy says nothing about how much acid is actually reaching the esophagus, and many patients with NERD have substantial, symptom-driving acid exposure (Gyawali et al., Annals of the New York Academy of Sciences, 2018).

The defining challenge of NERD is that a normal endoscopy groups together several very different conditions. Modern (Rome IV) classification separates patients with heartburn and a normal endoscopy into three categories: true NERD (abnormal esophageal acid exposure on pH testing), reflux hypersensitivity (normal acid exposure but symptoms clearly triggered by reflux events), and functional heartburn (normal acid exposure and no relationship between symptoms and reflux) (Roman et al., Yamada's Textbook of Gastroenterology, 2022). Only the first is a true GERD phenotype; the latter two are functional esophageal disorders driven by a hypersensitive esophagus rather than by acid (Patel et al., Clinical Gastroenterology and Hepatology, 2021). This distinction is the entire basis of treatment — true NERD responds well to acid suppression and, when appropriate, to antireflux surgery, while the functional mimics do not (see our PPI-Refractory GERD page and our GERD / Acid Reflux pillar) (Gyawali et al., Annals of the New York Academy of Sciences, 2018).

‍

NERD arises from the reflux of gastric contents into the esophagus in a person whose esophageal lining does not develop visible erosions despite the acid exposure (Fass et al., Nature Reviews Disease Primers, 2021). Several interacting mechanisms explain why symptoms occur without endoscopic damage:

• Pathologic acid (or weakly acidic) reflux, often related to transient relaxations of the lower esophageal sphincter or a weak antireflux barrier, delivering refluxate to a sensitive esophagus; many NERD patients have predominantly weakly acidic reflux (Li et al., Trials, 2022).

• Impaired esophageal mucosal integrity, in which microscopic widening of the spaces between epithelial cells (dilated intercellular spaces) allows acid to stimulate pain nerves without producing visible breaks (Park et al., Scientific Reports, 2020).

• Esophageal hypersensitivity, a heightened perception of normal or near-normal reflux, which plays a larger role in non-erosive disease than in erosive esophagitis (Fung, Drugs, 2025).

• A mechanically weak esophagogastric junction or hiatal hernia, which permits reflux the esophagus cannot clear efficiently (see our Hiatal & Paraesophageal Hernia page) (Gyawali et al., Annals of the New York Academy of Sciences, 2018).

‍

The risk factors for NERD overlap with those for GERD generally (Fass, New England Journal of Medicine, 2022):

• Obesity (body mass index over 30), which increases intra-abdominal pressure and reflux burden.

• Age 50 or older.

• Current smoking and alcohol use.

• Hiatal hernia (see our Hiatal & Paraesophageal Hernia page).

• Late or large meals and lying down soon after eating.

• Female sex, which is more strongly associated with the non-erosive phenotype and with functional overlap than with erosive disease (Park et al., Scientific Reports, 2020).

• Psychological factors such as anxiety and stress, which are more common in NERD and amplify symptom perception (Park et al., Scientific Reports, 2020).

‍

In NERD, reflux of acid and other gastric contents reaches the esophageal lining and stimulates sensory nerves, producing the sensation of heartburn and the symptom of regurgitation, even though the lining does not break down into visible erosions (Fass et al., Nature Reviews Disease Primers, 2021). At the microscopic level, the protective barrier of the esophageal epithelium is subtly compromised — the intercellular spaces widen — allowing acid to penetrate and trigger pain even without overt tissue destruction (Park et al., Scientific Reports, 2020). In many patients an element of visceral hypersensitivity means the esophagus "feels" reflux more intensely than normal, which is why symptom severity in NERD correlates poorly with the amount of visible damage (Fung, Drugs, 2025). Importantly, NERD and erosive esophagitis behave as biologically distinct conditions rather than simply mild versus severe versions of the same disease, and NERD generally does not progress to erosive disease over time in most patients (Fass et al., Nature Reviews Disease Primers, 2021).

‍

NERD is generally a non-progressive condition, which is reassuring, but it is not without consequences (Fass et al., Nature Reviews Disease Primers, 2021):

• Limited progression to erosive esophagitis. Over time, only about 10% of NERD patients progress to (usually low-grade) erosive esophagitis, and progression to Barrett's esophagus is uncommon in true non-erosive disease (Fass et al., Nature Reviews Disease Primers, 2021).

• Barrett's esophagus and esophageal adenocarcinoma. This long-term risk is primarily associated with chronic erosive reflux rather than non-erosive disease, but any patient with persistent or uncertain reflux warrants appropriate endoscopic evaluation (see our Barrett's Esophagus page) (Fass et al., Nature Reviews Disease Primers, 2021).

• Substantial impairment of quality of life. Despite the normal-appearing esophagus, NERD can cause symptoms every bit as bothersome as erosive disease and significantly affects daily function, sleep, and well-being (Gyawali et al., Annals of the New York Academy of Sciences, 2018).

• Chronicity and symptom relapse. NERD is a chronic condition; about two-thirds of PPI-responsive patients relapse symptomatically when the medication is stopped (Katz et al., ACG Clinical Guideline, 2022).

‍

‍

The symptoms of NERD are the typical symptoms of reflux disease, present despite a normal endoscopy (Fass, New England Journal of Medicine, 2022):

• Heartburn — a burning discomfort behind the breastbone, the hallmark symptom.

• Regurgitation of acid or food into the throat or mouth.

• Chest discomfort or non-cardiac chest pain.

• Dysphagia (difficulty swallowing) in some patients, which always warrants evaluation (Roman et al., Yamada's Textbook of Gastroenterology, 2022).

• Extraesophageal symptoms such as chronic cough, hoarseness, or globus sensation, which are the least specific for reflux (Roman et al., Yamada's Textbook of Gastroenterology, 2022).

Alarm features — difficulty swallowing, unintentional weight loss, gastrointestinal bleeding or anemia, or vomiting — require prompt endoscopy to exclude stricture or malignancy (Fass, New England Journal of Medicine, 2022).

‍

Because the esophagus appears normal, the diagnosis of NERD depends on objective testing to confirm that reflux is truly present and is driving the symptoms — the same rigorous principle that underlies the workup of refractory reflux (Patel et al., Clinical Gastroenterology and Hepatology, 2021):

• Upper endoscopy (EGD), which by definition shows no mucosal breaks and excludes erosive esophagitis, Barrett's esophagus, stricture, and eosinophilic esophagitis (Fass et al., Nature Reviews Disease Primers, 2021).

• Ambulatory reflux monitoring (pH or pH-impedance), performed off acid-suppressing therapy, which is the decisive test — it measures esophageal acid exposure time and the association between symptoms and reflux events, separating true NERD (abnormal acid exposure) from reflux hypersensitivity and functional heartburn (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

• High-resolution esophageal manometry, required to diagnose functional heartburn, to assess peristalsis before any antireflux procedure, and critically to exclude achalasia, which can masquerade as reflux (see our Achalasia page) (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

• A PPI trial, which can support a presumptive diagnosis of GERD when symptoms clearly respond, though a normal endoscopy plus objective reflux testing remains the reference standard for distinguishing NERD from its functional mimics (Maret-Ouda et al., JAMA, 2020)

‍

The core diagnostic task in a patient with heartburn and a normal endoscopy is distinguishing true NERD from the functional esophageal disorders — a distinction that determines whether acid-directed therapy or antireflux surgery will work at all (Patel et al., Clinical Gastroenterology and Hepatology, 2021):

• Functional heartburn — heartburn with normal esophageal acid exposure and no symptom-reflux association; it is not a GERD phenotype and does not respond to acid suppression or antireflux surgery, being treated instead with neuromodulators and behavioral therapy (Roman et al., Yamada's Textbook of Gastroenterology, 2022).

• Reflux hypersensitivity — normal acid exposure but a positive symptom-reflux association; it is considered a functional disorder and is only a partial, not a primary, surgical target (Roman et al., Yamada's Textbook of Gastroenterology, 2022).

• PPI-refractory GERD — persistent symptoms despite therapy, which requires the same objective phenotyping (see our PPI-Refractory GERD page) (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

• Eosinophilic esophagitis — a common cause of esophageal symptoms with a near-normal or subtly abnormal endoscopy, diagnosed on biopsy.

• Achalasia and other motility disorders — excluded by manometry (see our Achalasia page) (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

‍

Lifestyle measures are a foundational, first-line part of NERD management and are particularly valuable because they help across the entire spectrum of reflux-like symptoms regardless of whether acid is the main driver (Steinman, AGS Beers Criteria, 2025):

• Weight loss in overweight and obese patients — the measure with the strongest supporting evidence (Steinman, AGS Beers Criteria, 2025).

• Avoiding meals within 2–3 hours of bedtime and elevating the head of the bed for nighttime symptoms (Zikos et al., Current Gastroenterology Reports, 2020).

• Smoking cessation and reducing alcohol.

• Avoiding individual trigger foods.

• Stress-reduction and relaxation strategies, which are especially relevant given the role of esophageal hypervigilance in the non-erosive phenotype (Steinman, AGS Beers Criteria, 2025).

These measures do not correct a mechanical problem such as a large hiatal hernia (see our Hiatal & Paraesophageal Hernia page) (Zikos et al., Current Gastroenterology Reports, 2020).

‍

Treatment of NERD is stepwise and depends on whether reflux has been objectively confirmed (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

Medical therapy (first-line):

• Proton pump inhibitors (PPIs) are the mainstay and are superior to H2-receptor antagonists in NERD, though the response rate is lower than in erosive disease — pooled symptom response at 4 weeks is roughly 37% in NERD versus 56% in erosive esophagitis, largely because the "NERD" label in trials has historically included functional patients who do not respond to acid suppression (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

• On-demand or intermittent PPI therapy is an acceptable and often preferred strategy in NERD; in a randomized trial, 83% of NERD patients on on-demand omeprazole remained in remission at 6 months versus 56% on placebo (Katz et al., ACG Clinical Guideline, 2022).

• Step-down to an H2-receptor antagonist is a reasonable maintenance option, particularly in NERD (Katz et al., ACG Clinical Guideline, 2022).

• Potassium-competitive acid blockers (vonoprazan) are an option when acid suppression is inadequate; vonoprazan is FDA-approved for relief of heartburn associated with non-erosive GERD and provides faster, more durable acid suppression (FDA Orange Book, 2024; Fung, Drugs, 2025).

• Adjunctive agents and neuromodulators — alginates, nighttime H2-receptor antagonists, and, where functional overlap is present, neuromodulators and behavioral therapy (Steinman, AGS Beers Criteria, 2025).

Procedural and surgical therapy (only after reflux is objectively confirmed and functional disorders and achalasia excluded):

• Laparoscopic antireflux surgery (fundoplication) has a definitive role in carefully selected NERD patients with objectively proven reflux and persistent symptoms, especially when the esophagogastric junction is compromised; the single best predictor of a good surgical outcome is a prior response to a PPI (see our Nissen Fundoplication and antireflux surgery pages) (Gyawali et al., Annals of the New York Academy of Sciences, 2018). Patient selection is critical, because NERD patients overall have lower symptom-improvement rates, higher dissatisfaction, and more postoperative dysphagia after fundoplication than erosive-disease patients — a difference driven by the functional patients who should not have been operated on (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

• Magnetic sphincter augmentation (LINX) and transoral incisionless fundoplication (TIF) are additional options in appropriately selected patients with objectively confirmed reflux (see our LINX and TIF pages) (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

‍

Evaluation is warranted for heartburn, regurgitation, or chest discomfort that occurs frequently (mild symptoms on two or more days a week, or moderate-to-severe symptoms weekly), and promptly for any alarm feature — difficulty swallowing, unintentional weight loss, vomiting, or signs of gastrointestinal bleeding (Fass, New England Journal of Medicine, 2022). Patients whose reflux symptoms persist despite a normal endoscopy should undergo formal esophageal testing rather than open-ended medication escalation, because a normal endoscopy alone cannot distinguish true NERD from a functional disorder (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

‍

Referral for a dedicated antireflux evaluation is appropriate for patients with objectively confirmed, acid-driven NERD whose symptoms persist despite optimized medical therapy, for those who do not wish to take long-term medication, and for those with regurgitation-predominant symptoms or a hiatal hernia (Gyawali et al., Annals of the New York Academy of Sciences, 2018). Because surgical success in NERD depends so heavily on correct patient selection, referral should be to an experienced foregut surgeon who will complete objective testing — endoscopy, ambulatory reflux monitoring, and manometry — before recommending any procedure (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

‍

Most patients with correctly diagnosed NERD do well over the long term, but reflux disease is chronic and symptoms commonly recur if treatment is stopped, so a sustainable long-term plan matters more than a single course of therapy (Katz et al., ACG Clinical Guideline, 2022). For many, the lowest effective PPI dose, on-demand dosing, or step-down to an H2-receptor antagonist provides durable control while minimizing medication exposure (Katz et al., ACG Clinical Guideline, 2022). The patients who benefit most from a definitive procedure are precisely those in whom testing has proven acid-driven reflux and documented a PPI response — which is why an integrated foregut program that phenotypes the disease accurately, manages weight as the key modifiable factor, and matches therapy to the true mechanism produces the best long-term results (see our GERD / Acid Reflux pillar) (Gyawali et al., Annals of the New York Academy of Sciences, 2018).

‍

The prognosis of NERD is generally favorable: it is typically a non-progressive condition, and only about 10% of patients progress to (usually low-grade) erosive esophagitis over time (Fass et al., Nature Reviews Disease Primers, 2021). Symptom control is achievable in most patients, though it tends to require ongoing therapy, and about two-thirds of PPI-responsive patients relapse when medication is stopped — which is why on-demand and step-down strategies are so useful in this group (Katz et al., ACG Clinical Guideline, 2022). For patients with objectively proven, acid-driven NERD who respond to a PPI, the outlook after appropriately selected antireflux surgery is good; for those whose symptoms stem from functional heartburn or reflux hypersensitivity, the outlook is also good but depends on neuromodulatory and behavioral treatment rather than surgery (Patel et al., Clinical Gastroenterology and Hepatology, 2021).

‍

Non-erosive reflux disease is where reflux care most often goes wrong, because a normal endoscopy is frequently misread as either trivial reflux or as proof that surgery will help — and both assumptions lead to poor outcomes. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, is a fellowship-trained, board-certified minimally invasive foregut and bariatric surgeon in Miami with extensive experience across the full spectrum of antireflux therapy — laparoscopic and robotic fundoplication, magnetic sphincter augmentation (LINX), transoral incisionless fundoplication (TIF), hiatal and paraesophageal hernia repair, and Roux-en-Y gastric bypass as an antireflux operation. His practice insists on complete, objective evaluation — endoscopy, ambulatory reflux monitoring, and high-resolution manometry — before any intervention, so that true acid-driven NERD is distinguished from functional heartburn and reflux hypersensitivity, achalasia is never missed, and the patients most likely to benefit from a procedure are precisely the ones selected for it. Patients benefit from an integrated foregut program, evidence-based medical management, and structured long-term follow-up.

‍